MicroRNA signatures in liver diseases

Xian-Ming Chen

Xian-Ming Chen, Department of Medical Microbiology and Immunology, Creighton University Medical Center, Criss II, Room 529, 2500 California Plaza, Omaha, NE 68178, United States

Author contributions: Chen XM wrote the paper.

Supported by National Institute of Health grant (R01 AI071321) and the Tobacco Settlement Foundation of Nebraska (LB 692)

Correspondence to: Xian-Ming Chen, MD, Associate Professor, Department of Medical Microbiology and Immunology, Creighton University Medical Center, Criss II, Room 529, 2500 California Plaza, Omaha, NE 68178, United States. xianmingchen@creighton.edu Telephone: +1-402-2803750 Fax: +1-402-2801875

Received: February 6, 2009 Revised: March 3, 2009 Accepted: March 10, 2009 Published online: April 14, 2009

Abstract

MicroRNAs (miRNAs) are an emerging class of highly conserved non-coding small RNAs that regulate gene expression at the post-transcriptional level. It is now clear that miRNAs can potentially regulate every aspect of cellular activity, including differentiation and development, metabolism, proliferation, apoptotic cell death, viral infection and tumorigenesis. Recent studies provide clear evidence that miRNAs are abundant in the liver and modulate a diverse spectrum of liver functions. Deregulation of miRNA expression may be a key pathogenetic factor in many liver diseases including viral hepatitis, hepatocellular cancer and polycystic liver diseases. A clearer understanding of the mechanisms involved in miRNA deregulation will offer new diagnostic and therapeutic strategies to treat liver diseases. Moreover, better understanding of miRNA regulation and identification of tissue-specific miRNA targets employing transgenic/knockout models and/or modulating oligonucleotides will improve our knowledge of liver physiology and diseases.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: MicroRNAs; Non-coding RNAs; Liver; Tumorigenesis; Gene regulation

Peer reviewer: Dr. Bart Rik De Geest, Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, Leuven 3000, Belgium

INTRODUCTION

Genomic studies have demonstrated that many portions of the human genome do not encode conventional protein-coding genes but encode biologically active non-coding RNA species[1]. With the development of small RNA interface techniques over the past decade, it becomes clear that many small RNA molecules could regulate gene and protein expression. One class of such small non-coding RNAs is microRNAs (miRNAs), a group of regulatory RNAs of 19-22 nucleotides involved in control of gene expression at the post-transcriptional level[2]. Recent studies suggest that miRNAs are involved in regulating cell fate (cell death and proliferation), initiation and progression of human cancer, developmental timing, and inflammatory responses[3-6]. Modulation of miRNA expression in vitro as well as in vivo has revealed an important role of miRNAs in liver functions. In this review, we appraise the recent findings on miRNAs in liver physiology and disease. We will also discuss the development and use of miRNA antagonists (antagomirs) to target miRNAs in vivo, which may translate into novel therapeutic strategies for liver disease in the future.

miRNAs ARE REGULATORY NON-CODING SMALL RNAs IMPORTANT TO POST-TRANSCRIPTIONAL GENE REGULATION

miRNAs are endogenous, single-stranded RNA molecules consisting of approximately 22 non-coding nucleotides that regulate target genes[2-8]. miRNA molecules have been identified in over 80 species including those encoded by viral genomes. There are approximately 500-1000 different mammalian miRNA genes; a complete list and details about the nomenclature of the miRNAs can be viewed at Sanger mirBase 10.1 (http://microrna.sanger.ac.uk/sequences/) [9]. Up to 600 miRNAs have been identified in humans[10].

Most miRNAs are generated by RNA polymerase
miRNAS ARE ABUNDANT AND FINELY REGULATED IN THE LIVER

One of the first clues of the existence of miRNAs in mammals came from studies on genetic alterations in liver tumors. An unusual transcript, named her, was described and characterized as liver-specific, essentially non-coding, specifically nuclear, and processed by endonucleases in one of woodchuck liver tumors investigated in 1989\[^{[18]}\]. Later on, the her transcript was found to encompass the so-called “pri-miRNA” for miR-122\[^{[19]}\]. miRNA-122 was later described as a liver specific miRNA and has been reported in mouse, woodchuck and human livers, in human primary hepatocytes, and in cultured liver derived cells\[^{[19,20]}\]. Besides miR-122, many other miRNAs, such as miR-1, miR-16, miR-27b, miR-30d, miR-126, miR-133, miR-143, and the let-7 family, are also abundantly expressed in adult liver tissue. While miR-122 appears as the most highly expressed miRNA in adult liver, miR-92a and miR-483 seem to be more specifically expressed in the fetal liver (Table 1)\[^{[21]}\]. Thus, the liver displays a differential miRNA expression profile during its development.

The liver contains many cell types including parenchymal cells (i.e. hepatocytes) and “non-parenchymal cells” which include endothelial cells, stellate cells, lymphoid cells, and biliary epithelial cells (cholangiocytes). Each cell type may have completely distinct miRNA expression profiles. However, miRNA expression profile in those cell types, in particular from humans, is not fully tested yet. Current understanding is limited to available human cell lines. For example, a distinct expression profile of miRNAs has been identified in H69 cells, a cell line of SV40 transformed human cholangiocytes\[^{[22-23]}\].

The molecular mechanisms underlying transcriptional regulation of miRNA genes in the liver remain largely unknown. Hepatocyte nuclear factor 1α (HNF-1α) is a hepatocyte-enriched transcription factor. Manipulation of HNF-1α function through RNA interference causes reciprocal changes in miR-107 expression and thus, may be involved in the regulation of miR-107 transcription in the liver\[^{[24]}\]. The myocyte enhancer factor-2 transcription factor can increase the expression of miR-1-2 and miR-133a-1\[^{[25]}\]. The transcription factor Myc can up-regulate the expression of miR17-92 cluster and down-regulate several other miRNAs in tumorigenesis\[^{[26]}\]. However, whether these transcription factors are also involved in the transcriptional regulation of those miRNAs in the liver is unclear. In addition, decrease of let-7 family expression in human cholangiocytes in response to microbial stimulation appears to be nuclear factor (NF)-κB-dependent\[^{[25]}\]. On the other hand, the functional expression of transcription factors can also be regulated by miRNAs, as it has recently been shown for signal transducer and activator of transcription 3 (STAT-3)\[^{[23]}\].

miRNAS MAY BE KEY PLAYERS IN THE REGULATION OF LIVER FUNCTIONS

For a comprehensive understanding of miRNA function and potential therapeutic use in liver physiology and disease, identification and validation of miRNA targets are of fundamental importance. Several bioinformatic methods have been developed to predict miRNA targets\[^{[7]}\]. Arora and Simpson adapted the 'ranked ratio

---

**Figure 1** miRNA biogenesis and function in animal cells. Animal genomes have specific genes that encode miRNAs. Primary miRNA transcripts (pri-miRNAs) are processed into precursor miRNA (pre-miRNAs) stem-loops of approximately 60 nucleotides in length by the nuclear RNase III enzyme Drosha. These pre-miRNAs are then incorporated into the RNA-induced silencing complex (RISC) and interfere with the regulation of mRNA translation by targeting mRNAs resulting in mRNA degradation or translational repression.

---
The minus sign is used to indicate very low to undetectable levels and one plus to three pluses indicate a gradual expression from low levels to very high levels. The slash stands for the miRNAs that were not assayed. This figure is modified from Girard et al[27] with the permission of the authors and the publisher.

(RR) described by Yu et al[27] and predicted the genes that are potentially targeted miRNAs in the liver[28]. This RR value is an indicator of the distribution of miRNA target genes within a single mRNA population. A high RR indicates low expression in a greater proportion of target genes and is, therefore, indicative of miRNA expression in that tissue. The RR values for all miRNAs were calculated for the miRNAs in the liver[28] and are shown in Figure 2. Clearly, many miRNAs could be the targets for miRNAs in the liver.

Validation of those potential targets for each miRNA requires experimental studies both in vitro and in vivo.

![Table 1 Repertoire of miRNAs in human liver](image)

| miRNA     | Atlas  | Adult | Fetal | miRNA     | Atlas  | Adult | Fetal |
|-----------|--------|-------|-------|-----------|--------|-------|-------|
| miR-122   | ++     | ++    | ++    | miR-154   | +      | /     | /     |
| miR-126   | ++     | /     | /     | miR-193a  | +      | /     | /     |
| miR-16    | ++     | ++    | /     | miR-193b  | +      | /     | /     |
| let-7a    | ++     | ++    | /     | miR-195   | +      | /     | /     |
| miR-22    | ++     | ++    | /     | miR-199a  | ++     | ++    | +     |
| miR-125b  | ++     | ++    | /     | miR-21    | ++     | ++    | +     |
| miR-143   | ++     | ++    | /     | miR-223   | +      | /     | /     |
| let-7b    | ++     | ++    | /     | miR-25    | +      | +     | +     |
| miR-99a   | ++     | ++    | /     | miR-27a   | +      | ++    | +     |
| let-7c    | ++     | ++    | /     | miR-29b   | +      | /     | /     |
| miR-181a  | /      | /     | /     | miR-29c   | +      | /     | /     |
| miR-194   | ++     | ++    | /     | miR-3-c   | ++     | ++    | +     |
| miR-451   | ++     | /     | /     | miR-32    | +      | /     | /     |
| miR-3-d   | ++     | ++    | /     | miR-37    | +      | /     | /     |
| miR-15b   | /      | /     | /     | miR-38    | +      | /     | /     |
| miR-193a-5p| ++    | /     | /     | miR-42    | +      | /     | /     |
| miR-24    | ++     | +++   | ++    | miR-425   | +      | /     | /     |
| miR 29a   | /      | /     | /     | miR-486-5p| +      | +     | +     |
| miR-23b   | /      | +     | +     | miR-5-5   | +      | /     | /     |
| miR-26b   | /      | /     | /     | miR-874   | +      | /     | /     |
| miR-27b   | /      | /     | /     | miR-885-5p| +      | /     | /     |
| miR-3-a   | /      | /     | /     | miR-1-7   | Traces | /     | /     |
| miR-92a   | /      | /     | /     | miR-424   | +      | /     | /     |
| miR-13-a  | /      | /     | /     | miR-98    | Traces | /     | /     |
| miR-15a   | /      | /     | /     | miR-3-b   | --     | ++    | +     |
| miR-186   | /      | /     | /     | miR-34    | --     | ++    | +     |
| miR-191   | /      | /     | /     | miR-1-6a  | --     | ++    | +     |
| miR-20a   | /      | /     | /     | miR-125a  | --     | ++    | +     |
| miR-28    | /      | /     | /     | miR-146   | --     | ++    | +     |
| miR-1-7   | /      | /     | /     | miR-149   | --     | ++    | +     |
| let-7b    | /      | /     | /     | miR-189   | --     | ++    | +     |
| miR-17    | /      | /     | /     | miR-199b  | --     | ++    | +     |
| miR-185   | /      | /     | /     | miR-21    | --     | ++    | +     |
| miR-192   | /      | /     | /     | miR-321   | --     | ++    | +     |
| miR-3-e   | /      | /     | /     | miR-145   | --     | ++    | +     |
| miR-381   | /      | /     | /     | miR-93    | --     | +     | +     |
| miR-96b   | /      | /     | /     | miR-483   | +      | ++    | +     |
| miR-1-3   | /      | /     | /     | miR-484   | --     | +     | +     |
| miR-23a   | /      | /     | /     | miR-485   | --     | +     | +     |
| let-7f    | /      | /     | /     | miR-487   | --     | +     | +     |
| let-7g    | /      | /     | /     | miR-2-    | --     | ++    | +     |
| miR-139-5p| /      | /     | /     | miR-18    | --     | +     | +     |
| miR-14-   | /      | /     | /     | miR-19b   | --     | +     | +     |
| miR-142   | /      | /     | /     | miR-1-6b  | --     | +     | +     |
| miR-144   | /      | /     | /     | miR-345   | +      | ++    | +     |
| miR-151   | /      | /     | /     | miR-41    | --     | +     | +     |

![Figure 2 Prediction of targets by miRNAs in the liver](image)

The miRNAs are ordered by RR values (upper-axis). The higher values reflect lower expression of predicted target genes and are, therefore, indicative of miRNA activity. The numbers of genes predicted to be targeted by each miRNA (lower-axis) are indicated by the grey line. This figure is reprinted from Arora and Simpson[28] with the permission of the authors and the publisher.

**Table 1 Repertoire of miRNAs in human liver**

The ATLAS and ADULT are calculated for the miRNAs in the liver.

**Figure 2 Prediction of targets by miRNAs in the liver.** The miRNAs are ordered by RR values (upper-axis). The higher values reflect lower expression of predicted target genes and are, therefore, indicative of miRNA activity. The numbers of genes predicted to be targeted by each miRNA (lower-axis) are indicated by the grey line. This figure is reprinted from Arora and Simpson[28] with the permission of the authors and the publisher.
miRNAs and liver diseases

miRNAs and viral hepatitis

Genes encoding miRNAs have also been found in viruses and viral miRNAs have a regulatory effect on their protein-coding genes[34]. This regulatory effect may be beneficial to the virus toward maintaining its replication, latency and evading the host immune system. Wu and colleagues analyzed the miRNA-encoding potential of the hepatitis B virus (HBV). Using computational approaches, the authors found that HBV putatively encodes only one candidate pre-miRNA. One viral miRNA was found to be targeted by the viral miRNA when they searched the target from viral miRNAs. Thus, HBV has evolved to use viral miRNAs as a means to regulate its own gene expression[35].

miRNAs from the host cells may play a role in building up direct or indirect effect in regulating viral genes[36-47]. Hepatitis C virus (HCV) is an enveloped RNA virus of the Flaviviridae family, which is capable of causing both acute and chronic hepatitis in humans by infecting liver cells. miRNA-122 has been reported to facilitate the replication of HCV, targeting the viral 5' non-coding region[38]. Indeed, HCV RNA can replicate in Huh 7 cells, which express miR-122, but not in HepG2 cells, which do not express miR-122. Silencing of miR-122 in hepatocytes resulted in a marked loss of replicating RNAs from HCV[38]. A putative miR-122 binding site in the 50-end of HCV genome was identified, suggesting a direct role of miR-122 in HCV replication[48]. An indirect effect of miR-122 inhibition on HCV regulation via the up-regulation of the cytoprotective enzyme heme-oxygenase 1 (HO-1) and the converse down-regulation of HO-1 repressor Bach1 was also characterized[39]. In addition, HCV replication is associated with an increase in expression of cholesterol biosynthesis genes that are regulated by miR-122[39].

On the other hand, Pedersen et al[40] demonstrated IFN-mediated modulation of the expression of numerous cellular miRNAs in the treatment of hepatocytes infected with HCV. Expression of a total of 30 cellular miRNAs in hepatocytes was influenced by IFN-α/β or IFN-γ. Specifically, eight of the miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296, miR-351, miR-431 and miR-448), having nearly perfect complementarity in their seed sequences with HCV RNA genomes, were up-regulated. Importantly, these miRNAs are capable of inhibiting HCV replication and infection. This has opened the door to our understanding of novel host–defense mechanisms that exist in mammalian cells as well as the antiviral mechanisms employed by interferon.

miRNAs and human hepatocellular cancer (HCC)

Several studies have shown that specific miRNAs are aberrantly expressed in malignant HCC cells or tissues compared to non-malignant hepatocytes or tissue[41-47]. Selected miRNAs such as miR-21, miR-224, miR-34a, miR-221/222, miR-106a, and miR-203 are up-regulated in HCC compared to benign hepatocellular tumors such as adenomas or focal nodular hyperplasia. Certain miRNAs have been noted to be decreased in HCC compared to non-tumoral tissue, such as miR-122a, miR-422h, miR-145, and miR-199a. Murakami et al[49] showed a correlation between miR-222, miR-106a, miR-92, miR-17-5p, miR-20, and miR-18 and the degree of differentiation suggesting an involvement of specific miRNAs in the progression of the disease. Interestingly, the altered expression of some miRNAs was associated
with distinctive risk factors, such as miR-96 with hepatitis B virus infection and miR-126* with alcohol use. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent non-tumoral liver, irrespective of viral association. In HCC patients with hepatitis C and liver cirrhosis, miR-122, miR-100, and miR-10a were overexpressed, whereas miR-198 and miR-145 were upregulated in primary liver carcinomas. Alteration of expression profile in HCC for some miRNAs may be the consequence of malignant transformation. For other miRNAs, they may play a role in the transformation process. miRNA-122 was reported to be significantly and specifically down-regulated in HCC in humans as well as in rodents. Amongst the putative target genes of miR-122 that can be predicted using computational tools, at least three are of interest in tumorigenesis: the gene for N-Myc, which is frequently overexpressed, whereas miR-198 and miR-145 were upregulated in five-fold down-regulated in hepatic tumors compared to normal liver parenchyma.

Alteration of expression profile in HCC for some miRNAs may be the consequence of malignant transformation. For other miRNAs, they may play a role in the transformation process. miRNA-122 was reported to be significantly and specifically down-regulated in HCC in humans as well as in rodents. Amongst the putative target genes of miR-122 that can be predicted using computational tools, at least three are of interest in tumorigenesis: the gene for N-Myc, which is frequently overexpressed, whereas miR-198 and miR-145 were upregulated in five-fold down-regulated in hepatic tumors compared to normal liver parenchyma.

miRNAS FOR THE DIAGNOSIS OF LIVER DISEASES

miRNAs could be of diagnostic significance for many liver diseases but current literature has been focused on tumors in the liver. Hepatocellular tumors comprise diverse benign and malignant neoplasms. Although the phenotypes can be broadly distinguished histologically or immunologically, these tumors can vary widely

Figure 3 Model of miR15a function in hepatic cystogenesis. A: In normal cholangiocytes, ciliary signaling activates intracellular signaling pathways resulting in PKD1 expression and CDC25A repression. Decreased levels of CDC25A then lead to G1 arrest, preventing cyst formation; B: In cholangiocytes of polycystic liver, miR15a level is reduced as a result of mutation of molecules important to the ciliary signaling. Reduction of miR15a results in elevated Cdc25A level, increased cell proliferation, and cyst growth. This figure is reprinted from Chu and Friedman with the permission of the authors and the publisher.
in their clinical behavior and prognosis. The use of miRNA-based classifications that correlate with etiology, pathogenetic changes, or malignant tendency will enhance molecular diagnosis and enable further definition of these phenotypes. In turn, this may yield clinically useful predictive markers of tumor behavior, as well as identify individual genetic and molecular contributors to tumorigenesis. Thus, miRNA profiling studies could be used for defining clinical phenotypes, as well as providing potentially useful molecular diagnostic markers.

Impairments in miRNA functioning seen in cancerogenesis can be used for determination of miRNA expression for diagnostics of tumor origin. Each type of cancer is characterized by a certain profile of miRNA expression. For example, the miRNA expression profiles in malignant hepatocytes differ from those of malignant cholangiocytes. Cluster analysis of miRNA expression profiles in tumors accurately determines not only type of the tissue (e.g. epithelium or hemopoietic system), but also discriminates tumors within the same type of tissue; this may reflect mechanism of transformation. Obviously, evaluation of miRNA profiles can be used for prognosis of the development of tumors. Such an approach for tumor diagnostics is very promising. However, it is not widely employed yet due to inadequately developed technology, lack of standards, requirements of very high purity of RNA samples, and not always reproducible results.

miRNAs AS THERAPEUTIC TARGETS FOR LIVER DISEASES

Development of miRNA/RNAi-based therapeutics requires several critical experimental steps, which include: (1) miRNA profiling of disease versus healthy tissue; (2) functional analysis of dysregulated miRNAs; and (3) in vivo studies with the use of different RNAi-based therapeutic methods to dysregulate miRNAs. The success of such strategies for gene therapy will provide clinicians with a larger repertoire that includes miRNA-therapeutic agents. For example, chemically engineered oligonucleotides, termed ‘antagomirs’, have recently been developed and proven to be efficient and specific silencers of endogenous miRNAs in mice. The silencing effect was considerably sustained over time probably because of a long half-life of endogenous miRNAs. In addition, induction of stable loss-of-function phenotypes for specific miRNAs by lentiviral-mediated antagomir expression has recently been described.

Over the past several years, strategies based on targeting HBV, and to a lesser extent HCV, by both synthetic and expressed activators of the RNAi pathway have proved efficient to inhibit viral replication both in vitro and in vivo. The recent study by Pedersen et al. provided great insights into validating sequence-predicted targets of cellular miRNAs within the HCV genome. miRNA-122 antagomir can down-regulate expression of several adult-liver genes, providing the potential to generate a new attractive expandable cell source for hepatocyte transplantation that would feature stem/progenitor cell phenotype. In addition, the effect of miR-122 antagomir in high-fat fed mice may be of therapeutic potential to reduce hepatic steatosis.

The important breakthrough in the field of hepatocarcinogenesis came from the accurate correlation of alterations in miRNAs with tumor proliferation and differentiation. So far, there have been very limited insights into this characterization. Recent studies by Meng et al. suggest a role for miRNAs in the influence of interleukin-6 in malignant cholangiocytes. MicroRNA-141, which showed strong overexpression in malignant cholangiocytes, was specifically localized in I2p, a region of known chromosomal aberration in biliary tract cancers. Inhibition of miR-21 sensitized the response of cholangiocarcinoma cell lines to chemotherapy. This observation gives rise to significant hope that miR-21 could serve as a biomarker for drug response in cholangiocarcinoma.

CONCLUSION

Study of miRNAs flourished during the decade after their discovery. It is now clear that miRNAs can potentially regulate every aspect of cellular activity, from differentiation and proliferation to apoptosis, and also modulate a large range of physiological processes from developmental timing to organogenesis. miRNAs also modulate a diverse spectrum of liver functions with developmental, (patho) physiological, and clinical implications. In the near future, the distinctive signature patterns of miRNA expression associated with liver cancer should allow classification of different stages in tumor progression. Further, creating artificial miRNAs with salutary effects by promoting the expression of beneficial gene products (e.g. tumor-suppressor proteins) or targeting viral genomes (e.g. molecules designed to specifically target HCV-genome sequences) may become part of our patient management and complement chemotherapy and antiviral treatments. Overall, unraveling the regulatory circuits of miRNAs in the liver is a great challenge, but may provide attractive targets for mechanism-based treatment of liver diseases.

REFERENCES

1. Kiss T. Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 2002; 109: 145-148
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
3. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355
4. Voinnet O. Induction and suppression of RNA silencing: insights from viral infections. Nat Rev Genet 2005; 6: 206-220
5. Nelson P, Kiriakidou M, Sharma A, Maniataki E, Mourelatos Z. The microRNA world: small is mighty. Trends Biochem Sci 2003; 28: 534-540
6. Taganov KD, Boldin MP, Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 2007; 26:
analysis of microRNA target gene expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos. Nucleic Acids Res 2008; 36:D154-D159

28 Arora A, Simpson DA. Individual mRNA expression profiles reveal the effects of specific microRNAs. Genome Biol 2008; 9: R82

29 Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689

30 Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Chen XM. miRNAs and liver diseases 1671

31 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798

32 Bhattacharyya SN, Habermacher R, Martine E, Closs EI, Jeang KT. RISCy business: MicroRNAs, principles of micro-RNA production and maturation. Oncogene 2005; 24: 3146-3152

33 Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-773

34 Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1933-1934

35 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20

36 Moroño T, Eitemble J, Bouguerel L, Hadchouel M, Tiollais P, Buendia MA. Structure and expression of hcr, a locus processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113

37 Chang J, Provost P, Taylor JM. Resistance of human hepatitis delta virus RNAs to dicer activity. J Virol 2003; 77: 11910-11917

38 Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113

39 Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Cauze A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656

40 Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282: 8256-8264

41 Chen XM, Splinter PL, O'Hara SP, LaRusso NF. A cellular microRNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007; 282: 28929-28938

42 Ladero Y, Couchy G, Balalaud C, Bouilac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 48: D154-D159

43 Liu N, Williams AH, Kim Y, McAnally J, Bezprozvanny S, Sutherland LB, Richardson JA, Bassel-Duby R, Olson EN. An intragenic MEF2-dependent enhancer directs musclespecific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 2007; 104: 20844-20849

44 Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Mgc. Proc Natl Acad Sci USA 2008; 105: 19678-19683

45 Yu Z, Jian Z, Shen SH, Purisima E, Wang E. Global
CM, Bolondi L, Negri M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Res* 2007; 67: 6092-6099

46 Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stat3. *Gastroenterology* 2008; 135: 257-269

47 Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. *Hepatology* 2008; 47: 1223-1232

48 Murakami Y, Yasuda T, Saijo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. *Oncogene* 2006; 25: 2537-2545

49 Chu AS, Friedman JR. A role for microRNA in cystic liver and kidney diseases. *J Clin Invest* 2008; 118: 3585-3587

50 Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. *J Clin Invest* 2008; 118: 3714-3724

51 Ryazansky SS, Gvozdev VA. Small RNAs and cancerogenesis. *Biochemistry (Mosc)* 2008; 73: 514-527

52 Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006; 6: 857-866

53 Thum T, Catalucci D, Bausersch J. MicroRNAs: novel regulators in cardiac development and disease. *Cardiovasc Res* 2008; 79: 562-570

54 Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. *Nature* 2005; 435: 834-838

55 Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res* 2004; 64: 3753-3756

56 Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 2006; 9: 189-198

57 Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NJ, Fabbri M, Iuliano R, Palumbo T, Pichiotti F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negri M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *N Engl J Med* 2005; 353: 1793-1801

58 Czech MP. MicroRNAs as therapeutic targets. *N Engl J Med* 2006; 354: 1194-1195

59 Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I, Ganser A, Eder M. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. *Nucleic Acids Res* 2007; 35: e149

60 Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. *Mol Ther* 2008; 16: 1105-1112

61 Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmitgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. *Gastroenterology* 2006; 130: 2113-2129

S- Editor Li LF  L- Editor Logan S  E- Editor Zheng XM